Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile

Archive ouverte

Tuloup, Vianney | France, Mathilde | Garreau, Romain | Bleyzac, Nathalie | Bourguignon, Laurent | Tod, Michel | Goutelle, Sylvain

Edité par CCSD ; American Society for Microbiology -

International audience. Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.

Consulter en ligne

Suggestions

Du même auteur

Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis

Archive ouverte | Reverchon, Jérémy | CCSD

International audience. Therapeutic drug monitoring (TDM) of tobramycin is widely performed in patients with cystic fibrosis (CF), but little is known about the value of model-informed precision dosing (MIPD) in thi...

Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction

Archive ouverte | Le Corvaisier, Claire | CCSD

International audience. Abstract The emergency contraceptive drugs (EC), levonorgestrel (LNG) and ulipristal acetate (UPA), are sensitive substrates of cytochrome P450 3A4 (CYP3A4). In 2016, the label of LNG was upd...

Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach

Archive ouverte | Tuloup, Vianney | CCSD

International audience. Chronic kidney disease (CKD) may alter drug renal elimination but is also known for interacting with hepatic metabolism via multiple uremic components. However, few global models, considering...

Chargement des enrichissements...